Last update:

Weight management news

Oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings

A study has found that an emerging class of GLP-1 weight-loss drugs suppresses eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain. This newly charted pathway—separate from ...

Abdominal obesity may lead to more severe menopause symptoms

Weight gain during menopause is common, with abdominal obesity being especially common and unhealthy. A new study based on data from the Study of Women's Health Across the Nation (SWAN) has found that in addition to its adverse ...

The critical role of exercise in the GLP-1 era

As GLP-1 receptor agonists reshape obesity treatment, a new medical perspective published in JAMA, underscores a persistent gap in care: integrating exercise into weight management in ways patients can sustain.

Gut hormone FGF15 changes how mice respond to weight loss

Nearly 40% of the population in the United States develop obesity, which is linked to the development of several diseases, including type 2 diabetes and metabolic liver disease. The rise in obesity is, in part, caused by ...

The GLP-1 paradox: Weight loss drugs may lead to stigma

Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss. From celebrity headlines to everyday conversations, GLP-1 drugs like Ozempic and Wegovy are often framed as breakthroughs ...

What to know about GLP-1 drugs for weight loss and health

As many of us know, keeping weight in check can be hard. National numbers certainly reflect this. Rates of overweight and obesity in the U.S. have steadily climbed since the early 1980s. The impact this has had on health ...